TP53 and pancreatic adenocarcinoma: Our study found that the expression levels of SUMO family members were significantly increased in PAAD tissues with TP53 mutations compared with PAAD with wild-type TP53, suggesting that SUMO family members may be downstream targets of mutant TP53.